Sana Biotechnology, Inc. (SANA) earnings date
Mar 11, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 41 days, typically, give or take 14 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | after close | 36 | 8-K |
| Q2 FY2026 | Mon, Aug 10, 2026 | after close | 41 | 8-K |
| Q1 FY2026 | Mon, May 11, 2026 | after close | 41 | 8-K |
| Q4 FY2025 | Tue, Mar 3, 2026 | after close | 62 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Mon, Aug 11, 2025 | after close | 42 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Mon, Mar 17, 2025 | after close | 76 | 8-K |
What they guided beta
| Q3 FY2026 | "Exhibit 99.1 Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without immunosuppression in type 1 diabetes Advancing strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerati" exhibit |
| Q3 FY2026 | "“We aim to share data from both of these programs in 2027 and anticipate both have the potential for relatively rapid proof of concept." exhibit |
| Q3 FY2026 | "The $3.7 million decrease for the nine months ended September 30, 2026 compared to the same period in 2025 was primarily due to lower personnel-related expenses, including non-cash stock-based compensation, lower facility and other allocated costs, and third-party manufacturing costs at CDMOs associated with the suspended allogeneic CAR T programs incurred in the prior-year period that did not recur in 2026." exhibit |
| Q2 FY2026 | "Exhibit 99.1 Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma and generating initial clinical data, including manufacturing and clinical trial readiness Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet" exhibit |
| Q2 FY2026 | "14-month data from the study were presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting in July 2026, and additional data from the IST will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 on October 2." exhibit |
| Q2 FY2026 | "Raised aggregate net proceeds of $93.3 million from sales of common stock through Sana’s at-the-market offering facility (ATM) and Mayo Clinic investment in the second quarter; expected cash runway into mid-2027." exhibit |
| Q2 FY2026 | "Raised net proceeds of $93.3 million in the second quarter from sales of common stock through Sana’s ATM and equity financing." exhibit |
| Q2 FY2026 | "The increase of $0.9 million for the three months ended June 30, 2026 compared to the same period in 2025 was primarily due to increased research, laboratory, and clinical development costs for our SC451 and SG293 programs and increased third-party manufacturing costs at contract development and manufacturing organizations (CDMOs) for our SC451 and SG293 programs, partially offset by lower personnel and other facility and allocated costs." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SANA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SANA
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/SANA/"><img src="https://veritasdata.dev/embed/SANA.svg" alt="SANA earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/SANA/)
Script
<script async src="https://veritasdata.dev/embed/SANA.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SANA"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.